Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $19.90.

A number of analysts recently issued reports on the company. Evercore initiated coverage on Oric Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $25.00 price objective for the company. Wall Street Zen lowered shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Oppenheimer boosted their price target on shares of Oric Pharmaceuticals from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Wolfe Research started coverage on shares of Oric Pharmaceuticals in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, Citigroup lifted their target price on shares of Oric Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a report on Monday, November 17th.

Oric Pharmaceuticals Stock Down 2.4%

Shares of ORIC opened at $9.99 on Monday. Oric Pharmaceuticals has a 52-week low of $3.90 and a 52-week high of $14.93. The stock has a fifty day simple moving average of $9.86 and a two-hundred day simple moving average of $10.87. The company has a market capitalization of $972.93 million, a PE ratio of -5.77 and a beta of 1.35.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. As a group, equities analysts anticipate that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Insider Activity

In other Oric Pharmaceuticals news, CEO Jacob Chacko sold 33,374 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $302,368.44. Following the sale, the chief executive officer directly owned 581,711 shares in the company, valued at $5,270,301.66. This represents a 5.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Dominic Piscitelli sold 10,720 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the sale, the chief financial officer directly owned 68,148 shares in the company, valued at $617,420.88. This represents a 13.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 54,814 shares of company stock valued at $496,615. 5.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in Oric Pharmaceuticals in the first quarter valued at approximately $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after buying an additional 3,131 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Oric Pharmaceuticals by 9.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after acquiring an additional 24,778 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Oric Pharmaceuticals by 1,331.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after acquiring an additional 473,600 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after acquiring an additional 11,198 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.